A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of
rhuMab 2C4 (Perjeta) and docetaxel (Taxotere) in participants with advanced solid tumors that
have progressed during or after standard therapy, or for which no standard therapy is
available. Participants will be enrolled and evaluated for dose-limiting toxicities (DLTs) in
escalating-dose cohorts in order to determine the maximum tolerated dose (MTD).